Orexo AB (publ)

Stockholm Stock Exchange ORX.ST

Orexo AB (publ) Price to Sales Ratio (P/S) on February 03, 2025: 0.90

Orexo AB (publ) Price to Sales Ratio (P/S) is 0.90 on February 03, 2025, a 18.56% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Orexo AB (publ) 52-week high Price to Sales Ratio (P/S) is 1.20 on June 12, 2024, which is 33.29% above the current Price to Sales Ratio (P/S).
Orexo AB (publ) 52-week low Price to Sales Ratio (P/S) is 0.46 on November 21, 2024, which is -48.39% below the current Price to Sales Ratio (P/S).
Orexo AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 0.84.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Stockholm Stock Exchange: ORX.ST

Orexo AB (publ)

CEO	Mr. Nikolaj Sorensen
IPO Date	Nov. 9, 2005
Location	Sweden
Headquarters	P.O. Box 303
Employees	113
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Mental Health Personal Care

Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Key trends

Past 5 years